Lyc.HCL holds promise as a potential therapeutic agent for ESCC as it targets TRIM22, a critical molecule, and modulates the JAK2/STAT3 and ERK signaling pathways. Here, TRIM22 is linked to esophageal squamous cell carcinoma.